Global Solid Tumor Therapeutics Market Size, Status, Research and Forecast 2019-2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 91

Report ID: 311021

In cancer, solid tumors are formed by aggregation of abnormal tissues that do not comprise of any liquid or cyst.
Increasing incidences of solid tumor among cancer patients and growing prevalence of various types of metastatic cancers are the major factors that are expected to drive the growth of the global solid tumor therapeutics market.
In 2018, the global Solid Tumor Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Solid Tumor Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Solid Tumor Therapeutics development in United States, Europe and China.

The key players covered in this study
Hoffmann-La Roche
Johnson & Johnson
Novartis
AstraZeneca
Biogen Idec
Boehringer Ingelheim
GlaxoSmithKline
Eli Lilly
Kyowa Hakko Kirin
Abbott Laboratories
Baxter International

Market segment by Type, the product can be split into
Chemotherapy
Hormone Therapy
Immunotherapy
Targeted Therapy

Market segment by Application, split into
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Cervical Cancer
Others

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Solid Tumor Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Solid Tumor Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Solid Tumor Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Solid Tumor Therapeutics Market Size Growth Rate by Type (2014-2025)
1.4.2 Chemotherapy
1.4.3 Hormone Therapy
1.4.4 Immunotherapy
1.4.5 Targeted Therapy
1.5 Market by Application
1.5.1 Global Solid Tumor Therapeutics Market Share by Application (2014-2025)
1.5.2 Breast Cancer
1.5.3 Lung Cancer
1.5.4 Colorectal Cancer
1.5.5 Prostate Cancer
1.5.6 Cervical Cancer
1.5.7 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Solid Tumor Therapeutics Market Size
2.2 Solid Tumor Therapeutics Growth Trends by Regions
2.2.1 Solid Tumor Therapeutics Market Size by Regions (2014-2025)
2.2.2 Solid Tumor Therapeutics Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Solid Tumor Therapeutics Market Size by Manufacturers
3.1.1 Global Solid Tumor Therapeutics Revenue by Manufacturers (2014-2019)
3.1.2 Global Solid Tumor Therapeutics Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Solid Tumor Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2 Solid Tumor Therapeutics Key Players Head office and Area Served
3.3 Key Players Solid Tumor Therapeutics Product/Solution/Service
3.4 Date of Enter into Solid Tumor Therapeutics Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Solid Tumor Therapeutics Market Size by Type (2014-2019)
4.2 Global Solid Tumor Therapeutics Market Size by Application (2014-2019)

5 United States
5.1 United States Solid Tumor Therapeutics Market Size (2014-2019)
5.2 Solid Tumor Therapeutics Key Players in United States
5.3 United States Solid Tumor Therapeutics Market Size by Type
5.4 United States Solid Tumor Therapeutics Market Size by Application

6 Europe
6.1 Europe Solid Tumor Therapeutics Market Size (2014-2019)
6.2 Solid Tumor Therapeutics Key Players in Europe
6.3 Europe Solid Tumor Therapeutics Market Size by Type
6.4 Europe Solid Tumor Therapeutics Market Size by Application

7 China
7.1 China Solid Tumor Therapeutics Market Size (2014-2019)
7.2 Solid Tumor Therapeutics Key Players in China
7.3 China Solid Tumor Therapeutics Market Size by Type
7.4 China Solid Tumor Therapeutics Market Size by Application

8 Japan
8.1 Japan Solid Tumor Therapeutics Market Size (2014-2019)
8.2 Solid Tumor Therapeutics Key Players in Japan
8.3 Japan Solid Tumor Therapeutics Market Size by Type
8.4 Japan Solid Tumor Therapeutics Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Solid Tumor Therapeutics Market Size (2014-2019)
9.2 Solid Tumor Therapeutics Key Players in Southeast Asia
9.3 Southeast Asia Solid Tumor Therapeutics Market Size by Type
9.4 Southeast Asia Solid Tumor Therapeutics Market Size by Application

10 India
10.1 India Solid Tumor Therapeutics Market Size (2014-2019)
10.2 Solid Tumor Therapeutics Key Players in India
10.3 India Solid Tumor Therapeutics Market Size by Type
10.4 India Solid Tumor Therapeutics Market Size by Application

11 Central & South America
11.1 Central & South America Solid Tumor Therapeutics Market Size (2014-2019)
11.2 Solid Tumor Therapeutics Key Players in Central & South America
11.3 Central & South America Solid Tumor Therapeutics Market Size by Type
11.4 Central & South America Solid Tumor Therapeutics Market Size by Application

12 International Players Profiles
12.1 Hoffmann-La Roche
12.1.1 Hoffmann-La Roche Company Details
12.1.2 Company Description and Business Overview
12.1.3 Solid Tumor Therapeutics Introduction
12.1.4 Hoffmann-La Roche Revenue in Solid Tumor Therapeutics Business (2014-2019)
12.1.5 Hoffmann-La Roche Recent Development
12.2 Johnson & Johnson
12.2.1 Johnson & Johnson Company Details
12.2.2 Company Description and Business Overview
12.2.3 Solid Tumor Therapeutics Introduction
12.2.4 Johnson & Johnson Revenue in Solid Tumor Therapeutics Business (2014-2019)
12.2.5 Johnson & Johnson Recent Development
12.3 Novartis
12.3.1 Novartis Company Details
12.3.2 Company Description and Business Overview
12.3.3 Solid Tumor Therapeutics Introduction
12.3.4 Novartis Revenue in Solid Tumor Therapeutics Business (2014-2019)
12.3.5 Novartis Recent Development
12.4 AstraZeneca
12.4.1 AstraZeneca Company Details
12.4.2 Company Description and Business Overview
12.4.3 Solid Tumor Therapeutics Introduction
12.4.4 AstraZeneca Revenue in Solid Tumor Therapeutics Business (2014-2019)
12.4.5 AstraZeneca Recent Development
12.5 Biogen Idec
12.5.1 Biogen Idec Company Details
12.5.2 Company Description and Business Overview
12.5.3 Solid Tumor Therapeutics Introduction
12.5.4 Biogen Idec Revenue in Solid Tumor Therapeutics Business (2014-2019)
12.5.5 Biogen Idec Recent Development
12.6 Boehringer Ingelheim
12.6.1 Boehringer Ingelheim Company Details
12.6.2 Company Description and Business Overview
12.6.3 Solid Tumor Therapeutics Introduction
12.6.4 Boehringer Ingelheim Revenue in Solid Tumor Therapeutics Business (2014-2019)
12.6.5 Boehringer Ingelheim Recent Development
12.7 GlaxoSmithKline
12.7.1 GlaxoSmithKline Company Details
12.7.2 Company Description and Business Overview
12.7.3 Solid Tumor Therapeutics Introduction
12.7.4 GlaxoSmithKline Revenue in Solid Tumor Therapeutics Business (2014-2019)
12.7.5 GlaxoSmithKline Recent Development
12.8 Eli Lilly
12.8.1 Eli Lilly Company Details
12.8.2 Company Description and Business Overview
12.8.3 Solid Tumor Therapeutics Introduction
12.8.4 Eli Lilly Revenue in Solid Tumor Therapeutics Business (2014-2019)
12.8.5 Eli Lilly Recent Development
12.9 Kyowa Hakko Kirin
12.9.1 Kyowa Hakko Kirin Company Details
12.9.2 Company Description and Business Overview
12.9.3 Solid Tumor Therapeutics Introduction
12.9.4 Kyowa Hakko Kirin Revenue in Solid Tumor Therapeutics Business (2014-2019)
12.9.5 Kyowa Hakko Kirin Recent Development
12.10 Abbott Laboratories
12.10.1 Abbott Laboratories Company Details
12.10.2 Company Description and Business Overview
12.10.3 Solid Tumor Therapeutics Introduction
12.10.4 Abbott Laboratories Revenue in Solid Tumor Therapeutics Business (2014-2019)
12.10.5 Abbott Laboratories Recent Development
12.11 Baxter International

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details